{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:25:44Z","timestamp":1791980744623,"version":"4.4.0"},"reference-count":234,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union \u2014 NextGenerationEU through the National Recovery and Resilience Plan of the Republic of Bulgaria","award":["BG-RRP-2.004-0004-C01"],"award-info":[{"award-number":["BG-RRP-2.004-0004-C01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antioxidants"],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is a heterogeneous neurodegenerative disorder in which oxidative stress represents a final common pathway linking diverse genetic and environmental insults to dopaminergic neuron loss. This review synthesizes evidence on how the commonly observed pathological changes in PD converge on excessive reactive oxygen species generation and redox imbalance. We present an overview on these pathways and key PD-linked genes that perturb mitochondrial quality control, lysosomal function, and inflammatory signaling, reinforcing oxidative stress. The major classes of redox-targeted therapeutic strategies under preclinical and clinical evaluation are outlined. Although many candidates show robust target engagement and neuroprotection in models, clinical trials have frequently yielded neutral or modest results, highlighting challenges related to brain delivery, off-target effects, optimal treatment window, and the fact that oxidative stress alone may be necessary but not sufficient to drive human disease progression. In the current paper, beyond cataloguing oxidative pathways, we explain the role of etiologic heterogeneity on biochemical target engagement and clinical outcomes. We outline subtype-enriched trial strategies and rational combination approaches. Targeting oxidative stress\u2013related pathways thus remains a promising avenue for disease modification in PD, provided that future interventions are mechanistically informed and adapted to patient-specific redox vulnerabilities.<\/jats:p>","DOI":"10.3390\/antiox15020187","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:48:08Z","timestamp":1770025688000},"page":"187","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sources of Oxidative Stress in Parkinson\u2019s Disease: Pathways and Therapeutic Implications"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1029-9870","authenticated-orcid":false,"given":"Yordan","family":"Yordanov","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Dunav 2 Str., 1000 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6859-9369","authenticated-orcid":false,"given":"Denitsa","family":"Stefanova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Dunav 2 Str., 1000 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kondeva-Burdina","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Dunav 2 Str., 1000 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Tzankova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Dunav 2 Str., 1000 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s Disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/mds.26354","article-title":"Disease-modifying Strategies for Parkinson\u2019s Disease","volume":"30","author":"Kalia","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_3","first-page":"6691390","article-title":"Oxidative Stress: A New Pathophysiological Pathway in Parkinson\u2019s Disease and a Potential Target of the Brain-Sport Crosstalk","volume":"2025","author":"Caproni","year":"2025","journal-title":"Park. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Yang, X., Yang, R., and Zhang, F. (2022). Role of Nrf2 in Parkinson\u2019s Disease: Toward New Perspectives. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.919233"},{"key":"ref_5","first-page":"461","article-title":"The Role of Oxidative Stress in Parkinson\u2019s Disease","volume":"3","author":"Dias","year":"2013","journal-title":"J. Park. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ni, A., and Ernst, C. (2022). Evidence That Substantia Nigra Pars Compacta Dopaminergic Neurons Are Selectively Vulnerable to Oxidative Stress Because They Are Highly Metabolically Active. Front. Cell. Neurosci., 16.","DOI":"10.3389\/fncel.2022.826193"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9843","DOI":"10.1073\/pnas.0403495101","article-title":"The Role of Iron and Copper Molecules in the Neuronal Vulnerability of Locus Coeruleus and Substantia Nigra during Aging","volume":"101","author":"Zecca","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2111643118","DOI":"10.1073\/pnas.2111643118","article-title":"Bach1 Derepression Is Neuroprotective in a Mouse Model of Parkinson\u2019s Disease","volume":"118","author":"Ahuja","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1212\/WNL.58.12.1809","article-title":"Oxidative Damage and Cytogenetic Analysis in Leukocytes of Parkinson\u2019s Disease Patients","volume":"58","author":"Migliore","year":"2002","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410360305","article-title":"Alterations in Glutathione Levels in Parkinson\u2019s Disease and Other Neurodegenerative Disorders Affecting Basal Ganglia","volume":"36","author":"Sian","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jnc.13731","article-title":"Mitochondrial Dysfunction in Parkinson\u2019s Disease","volume":"139","author":"Bose","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12035-013-8489-4","article-title":"Integrating Pathways of Parkinson\u2019s Disease in a Molecular Interaction Map","volume":"49","author":"Fujita","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"ref_13","unstructured":"(2026, January 23). PDTrialTracker.Info. Available online: http:\/\/www.pdtrialtracker.info."},{"key":"ref_14","first-page":"899","article-title":"Parkinson\u2019s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J. Park. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","article-title":"Mitochondrial Dysfunction in Parkinson\u2019s Disease\u2014A Key Disease Hallmark with Therapeutic Potential","volume":"18","author":"Henrich","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"ref_16","unstructured":"Stott, S. (2025, December 10). From NADPARK to NOPARK. Science of Parkinson\u2019s [Internet]. Available online: https:\/\/scienceofparkinsons.com\/2022\/03\/11\/nad-2\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00702-010-0482-8","article-title":"Neuropathology of Sporadic Parkinson Disease before the Appearance of Parkinsonism: Preclinical Parkinson Disease","volume":"118","author":"Ferrer","year":"2011","journal-title":"J. Neural Transm."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group SURE-PD Investigators, Schwarzschild, M.A., Ascherio, A., Beal, M.F., Cudkowicz, M.E., Curhan, G.C., Hare, J.M., Hooper, D.C., Kieburtz, K.D., and Macklin, E.A. (2014). Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol., 71, 141\u2013150.","DOI":"10.1001\/jamaneurol.2013.5528"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41531-022-00433-5","article-title":"Dose-Response Meta-Analysis on Urate, Gout, and the Risk for Parkinson\u2019s Disease","volume":"8","author":"Chang","year":"2022","journal-title":"npj Park. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1242\/dmm.026294","article-title":"Mitochondrial Dynamics in Parkinson\u2019s Disease: A Role for \u03b1-Synuclein?","volume":"10","author":"Falzone","year":"2017","journal-title":"Dis. Models Mech."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/brain\/awp058","article-title":"Mitochondrial Complex I Deficiency: From Organelle Dysfunction to Clinical Disease","volume":"132","author":"Distelmaier","year":"2008","journal-title":"Brain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.1038\/s41598-017-07181-0","article-title":"Mitochondrial Division Inhibitor-1 Is Neuroprotective in the A53T-\u03b1-Synuclein Rat Model of Parkinson\u2019s Disease","volume":"7","author":"Bido","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41586-021-03510-6","article-title":"Distinct Fission Signatures Predict Mitochondrial Degradation or Biogenesis","volume":"593","author":"Kleele","year":"2021","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ncb2012","article-title":"PINK1\/Parkin-Mediated Mitophagy Is Dependent on VDAC1 and P62\/SQSTM1","volume":"12","author":"Geisler","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/15548627.2021.1888244","article-title":"Regulation of PRKN-Independent Mitophagy","volume":"18","author":"Lapao","year":"2022","journal-title":"Autophagy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1080\/15548627.2022.2139080","article-title":"PINK1-PRKN Mediated Mitophagy: Differences between in vitro and in vivo Models","volume":"19","author":"Han","year":"2023","journal-title":"Autophagy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00125-015-3671-z","article-title":"The Hitchhiker\u2019s Guide to PGC-1\u03b1 Isoform Structure and Biological Functions","volume":"58","author":"Pettersson","year":"2015","journal-title":"Diabetologia"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Piccinin, E., Sardanelli, A.M., Seibel, P., Moschetta, A., Cocco, T., and Villani, G. (2021). PGC-1s in the Spotlight with Parkinson\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073487"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2174\/1389557521666210304112403","article-title":"Glitazones, PPAR-\u03b3 and Neuroprotection","volume":"21","author":"Kumar","year":"2021","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0304-3940(82)90390-1","article-title":"Parkinson\u2019s Disease: A Disorder Due to Nigral Glutathione Deficiency?","volume":"33","author":"Perry","year":"1982","journal-title":"Neurosci. Lett."},{"key":"ref_31","first-page":"114","article-title":"Brain Peroxidase and Catalase in Parkinson Disease","volume":"32","author":"Ambani","year":"1975","journal-title":"JAMA Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1326-6-8","article-title":"Glutathione Peroxidase 4 Is Associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson\u2019s Brain","volume":"6","author":"Bellinger","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ross, D., and Siegel, D. (2017). Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and Its Potential Role as a Redox Sensitive Molecular Switch. Front. Physiol., 8.","DOI":"10.3389\/fphys.2017.00595"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.neurobiolaging.2003.12.010","article-title":"Expression of NAD(P)H:Quinone Oxidoreductase in the Normal and Parkinsonian Substantia Nigra","volume":"25","author":"Bol","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Skou, L.D., Johansen, S.K., Okarmus, J., and Meyer, M. (2024). Pathogenesis of DJ-1\/PARK7-Mediated Parkinson\u2019s Disease. Cells, 13.","DOI":"10.3390\/cells13040296"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10863-019-09798-4","article-title":"Role of DJ-1 in the Mechanism of Pathogenesis of Parkinson\u2019s Disease","volume":"51","author":"Dolgacheva","year":"2019","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Szeliga, M. (2020). Peroxiredoxins in Neurodegenerative Diseases. Antioxidants, 9.","DOI":"10.3390\/antiox9121203"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1042\/BST0351119","article-title":"Mechanisms of Inflammatory Neurodegeneration: iNOS and NADPH Oxidase","volume":"35","author":"Brown","year":"2007","journal-title":"Biochem. Soc. Trans."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102660","DOI":"10.1016\/j.coi.2025.102660","article-title":"Microglia and Myeloperoxidase in Neuroinflammatory and Neurodegenerative Diseases","volume":"97","author":"Brunetta","year":"2025","journal-title":"Curr. Opin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Chen, Q., Chen, Y., Zhang, Y., Wang, F., Yu, H., Zhang, C., Jiang, Z., and Luo, W. (2019). Iron Deposition in Parkinson\u2019s Disease by Quantitative Susceptibility Mapping. BMC Neurosci., 20.","DOI":"10.1186\/s12868-019-0505-9"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4331\/wjbc.v5.i2.204","article-title":"Ceruloplasmin-Ferroportin System of Iron Traffic in Vertebrates","volume":"5","author":"Musci","year":"2014","journal-title":"World J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lazar-Poloczek, E., Romuk, E., Rozentryt, P., Duda, S., G\u0105sior, M., and Wojciechowska, C. (2021). Ceruloplasmin as Redox Marker Related to Heart Failure Severity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810074"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101890","DOI":"10.1016\/j.pneurobio.2020.101890","article-title":"Ferroptosis and Its Potential Role in the Physiopathology of Parkinson\u2019s Disease","volume":"196","author":"Bouchaoui","year":"2021","journal-title":"Prog. Neurobiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1007\/s12035-021-02320-1","article-title":"Thioredoxin-1 Rescues MPP+\/MPTP-Induced Ferroptosis by Increasing Glutathione Peroxidase 4","volume":"58","author":"Bai","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1196\/annals.1306.024","article-title":"Aceruloplasminemia: An Inherited Neurodegenerative Disease with Impairment of Iron Homeostasis","volume":"1012","author":"Xu","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15365","DOI":"10.1038\/s41598-023-42574-4","article-title":"Ferroptosis-Related Factors in the Substantia Nigra Are Associated with Parkinson\u2019s Disease","volume":"13","author":"Liu","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/jnc.12686","article-title":"Protective and Toxic Roles of Dopamine in Parkinson\u2019s Disease","volume":"129","author":"Paris","year":"2014","journal-title":"J. Neurochem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00004647-200202000-00011","article-title":"Increase in Dopamine Turnover Occurs Early in Parkinson\u2019s Disease: Evidence from a New Modeling Approach to PET 18 F-Fluorodopa Data","volume":"22","author":"Sossi","year":"2002","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-0-12-386467-3.00007-8","article-title":"Neuroprotective Profile of the Multitarget Drug Rasagiline in Parkinson\u2019s Disease","volume":"Volume 100","author":"Weinreb","year":"2011","journal-title":"International Review of Neurobiology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1021\/tx100182a","article-title":"Stable Expression of Short Interfering RNA for DT-Diaphorase Induces Neurotoxicity","volume":"23","author":"Lozano","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"15597","DOI":"10.1074\/jbc.M610893200","article-title":"Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine: ANALYSIS OF THE INTERACTIONS WITH \u03b1-SYNUCLEIN *","volume":"282","author":"Bisaglia","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/10715760902801533","article-title":"Dopamine (DA) Induced Irreversible Proteasome Inhibition via DA Derived Quinones","volume":"43","author":"Zhou","year":"2009","journal-title":"Free Radic. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1471-4159.2008.05541.x","article-title":"Neuromelanin Can Protect against Iron-Mediated Oxidative Damage in System Modeling Iron Overload of Brain Aging and Parkinson\u2019s Disease","volume":"106","author":"Zecca","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_54","first-page":"1","article-title":"Human Neuromelanin: An Endogenous Microglial Activator for Dopaminergic Neuron Death","volume":"5","author":"Zhang","year":"2013","journal-title":"Front. Biosci. Elite Ed."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1089\/ars.2011.4429","article-title":"Lipid Peroxidation Product 4-Hydroxy-2-Nonenal Promotes Seeding-Capable Oligomer Formation and Cell-to-Cell Transfer of \u03b1-Synuclein","volume":"18","author":"Bae","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"168144","DOI":"10.1016\/j.jmb.2023.168144","article-title":"Role of Autophagy Pathway in Parkinson\u2019s Disease and Related Genetic Neurological Disorders","volume":"435","author":"Themistokleous","year":"2023","journal-title":"J. Mol. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/jnc.12226","article-title":"Oxidative and Nitrative Alpha-Synuclein Modifications and Proteostatic Stress: Implications for Disease Mechanisms and Interventions in Synucleinopathies","volume":"125","author":"Schildknecht","year":"2013","journal-title":"J. Neurochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e1820","DOI":"10.1038\/cddis.2015.166","article-title":"Aggregated \u03b1-Synuclein and Complex I Deficiency: Exploration of Their Relationship in Differentiated Neurons","volume":"6","author":"Reeve","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lehtonen, \u0160., Sonninen, T.-M., Wojciechowski, S., Goldsteins, G., and Koistinaho, J. (2019). Dysfunction of Cellular Proteostasis in Parkinson\u2019s Disease. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.00457"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1038\/ncomms4828","article-title":"Mutation in VPS35 Associated with Parkinson\u2019s Disease Impairs WASH Complex Association and Inhibits Autophagy","volume":"5","author":"Zavodszky","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kuwahara, T., and Iwatsubo, T. (2020). The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.00227"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stemcr.2018.12.011","article-title":"Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson\u2019s Disease","volume":"12","author":"Carola","year":"2019","journal-title":"Stem Cell Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/s41418-018-0229-x","article-title":"Prevention of Neuronal Apoptosis by Astrocytes through Thiol-Mediated Stress Response Modulation and Accelerated Recovery from Proteotoxic Stress","volume":"25","author":"Gutbier","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Miao, Q., Wang, T., Wang, H., Yu, Y., and Jin, X. (2025). Loss of DJ-1 Alleviates Microglia-Mediated Neuroinflammation in Parkinson\u2019s Disease via Autophagy-Lysosomal Degradation of NLRP3. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1656729"},{"key":"ref_65","first-page":"2117","article-title":"Role of NLRP3 Inflammasome in Parkinson\u2019s Disease and Therapeutic Considerations","volume":"12","author":"Nguyen","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in Neurodegenerative Diseases: Mechanism and Potential Therapeutic Targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.freeradbiomed.2023.03.001","article-title":"Activation of Neuronal NADPH Oxidase NOX2 Promotes Inflammatory Neurodegeneration","volume":"200","author":"Tu","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00441-017-2626-8","article-title":"Myeloperoxidase-Immunoreactive Cells Are Significantly Increased in Brain Areas Affected by Neurodegeneration in Parkinson\u2019s and Alzheimer\u2019s Disease","volume":"369","author":"Gellhaar","year":"2017","journal-title":"Cell Tissue Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11302-008-9100-8","article-title":"Adenosine A2A Receptors in Parkinson\u2019s Disease Treatment","volume":"4","author":"Wojtczak","year":"2008","journal-title":"Purinergic Signal."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/jcp.30588","article-title":"LRRK2 and WAVE2 Regulate Microglial-Transition through Distinct Morphological Phenotypes to Induce Neurotoxicity in a Novel Two-Hit in Vitro Model of Neurodegeneration","volume":"237","author":"Fenner","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e31250","DOI":"10.1002\/jcp.31250","article-title":"LRRK2 Regulates Ferroptosis through the System Xc-GSH\u2013GPX4 Pathway in the Neuroinflammatory Mechanism of Parkinson\u2019s Disease","volume":"239","author":"Zheng","year":"2024","journal-title":"J. Cell. Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1007\/s10753-025-02291-8","article-title":"LRRK2 Mediates \u03b1-Synuclein-Induced Neuroinflammation and Ferroptosis through the P62-Keap1-Nrf2 Pathway in Parkinson\u2019s Disease","volume":"48","author":"Liu","year":"2025","journal-title":"Inflammation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"E5815","DOI":"10.1073\/pnas.1802179115","article-title":"Soluble Epoxide Hydrolase Plays a Key Role in the Pathogenesis of Parkinson\u2019s Disease","volume":"115","author":"Ren","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.21419","article-title":"Construction and Validation of a Parkinson\u2019s Disease Mutation Genotyping Array for the Parkin Gene","volume":"22","author":"Clark","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s Disease","volume":"5","author":"Breteler","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_76","first-page":"67","article-title":"Genetic Basis of Parkinson\u2019s Disease: Inheritance, Penetrance, and Expression","volume":"4","author":"Schulte","year":"2011","journal-title":"Appl. Clin. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100153","DOI":"10.1016\/j.neurop.2024.100153","article-title":"Genetics of Parkinson\u2019s Disease: Dominant Forms and GBA","volume":"4","author":"Salles","year":"2024","journal-title":"Neurol. Perspect."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of Novel Risk Loci, Causal Insights, and Heritable Risk for Parkinson\u2019s Disease: A Meta-Analysis of Genome-Wide Association Studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e200115","DOI":"10.1212\/NXG.0000000000200115","article-title":"Association of Family History and Polygenic Risk Score with Longitudinal Prognosis in Parkinson Disease","volume":"10","author":"Park","year":"2024","journal-title":"Neurol. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/ana.24335","article-title":"Polygenic Risk of Parkinson Disease Is Correlated with Disease Age at Onset","volume":"77","author":"Nalls","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e187800","DOI":"10.1001\/jamanetworkopen.2018.7800","article-title":"Association of Subthalamic Deep Brain Stimulation with Motor, Functional, and Pharmacologic Outcomes in Patients with Monogenic Parkinson Disease: A Systematic Review and Meta-Analysis","volume":"2","author":"Artusi","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1212\/WNL.0000000000001321","article-title":"GBA Mutations and Parkinson Disease","volume":"84","author":"Scholz","year":"2015","journal-title":"Neurology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-Synuclein Gene Identified in Families with Parkinson\u2019s Disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00401-019-02010-2","article-title":"Selective Vulnerability in \u03b1-Synucleinopathies","volume":"138","author":"Brimblecombe","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.1096284","article-title":"Hereditary Early-Onset Parkinson\u2019s Disease Caused by Mutations in PINK1","volume":"304","author":"Valente","year":"2004","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1126\/science.adu6445","article-title":"Structure of Human PINK1 at a Mitochondrial TOM-VDAC Array","volume":"388","author":"Callegari","year":"2025","journal-title":"Science"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ana.410440612","article-title":"Molecular Genetic Analysis of a Novel Parkin Gene in Japanese Families with Autosomal Recessive Juvenile Parkinsonism: Evidence for Variable Homozygous Deletions in the Parkin Gene in Affected Individuals","volume":"44","author":"Hattori","year":"1998","journal-title":"Ann. Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41531-024-00677-3","article-title":"Genotype\u2013Phenotype Correlation in PRKN-Associated Parkinson\u2019s Disease","volume":"10","author":"Menon","year":"2024","journal-title":"npj Park. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1077209","article-title":"Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism","volume":"299","author":"Bonifati","year":"2003","journal-title":"Science"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e202411078","DOI":"10.1083\/jcb.202411078","article-title":"The Reaction Mechanism for Glycolysis Side Product Degradation by Parkinson\u2019s Disease\u2013Linked DJ-1","volume":"224","author":"Watanabe","year":"2025","journal-title":"J. Cell Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2025.09.025","article-title":"DJ-1\/PARK7 in Parkinson\u2019s Disease: Mechanisms of Pathogenesis and Therapeutic Potential","volume":"587","author":"Bao","year":"2025","journal-title":"Neuroscience"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/ng1884","article-title":"Hereditary Parkinsonism with Dementia Is Caused by Mutations in ATP13A2, Encoding a Lysosomal Type 5 P-Type ATPase","volume":"38","author":"Ramirez","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Zhang, F., Wu, Z., Long, F., Tan, J., Gong, N., Li, X., and Lin, C. (2022). The Roles of ATP13A2 Gene Mutations Leading to Abnormal Aggregation of \u03b1-Synuclein in Parkinson\u2019s Disease. Front. Cell. Neurosci., 16.","DOI":"10.3389\/fncel.2022.927682"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","article-title":"Occurrence of Parkinson\u2019s Syndrome in Type 1 Gaucher Disease","volume":"89","author":"Neudorfer","year":"1996","journal-title":"QJM Int. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41531-025-00997-y","article-title":"Penetrance of Parkinson\u2019s Disease in GBA1 Carriers Depends on Variant Severity and Polygenic Background","volume":"11","author":"Hassanin","year":"2025","journal-title":"npj Park. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajhg.2011.06.001","article-title":"VPS35 Mutations in Parkinson Disease","volume":"89","author":"Wider","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ajhg.2011.06.008","article-title":"A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease","volume":"89","author":"Zimprich","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"eadj1205","DOI":"10.1126\/sciadv.adj1205","article-title":"Parkinson\u2019s VPS35[D620N] Mutation Induces LRRK2-Mediated Lysosomal Association of RILPL1 and TMEM55B","volume":"9","author":"Pal","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ana.21415","article-title":"Characterization of PLA2G6 as a Locus for Dystonia-Parkinsonism","volume":"65","author":"Bhatia","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e70059","DOI":"10.1111\/jnc.70059","article-title":"Altered Mitochondrial Bioenergetics and Calcium Kinetics in Young-Onset PLA2G6 Parkinson\u2019s Disease iPSCs","volume":"169","author":"Musthafa","year":"2025","journal-title":"J. Neurochem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the Gene Containing Mutations That Cause PARK8-Linked Parkinson\u2019s Disease","volume":"44","author":"Jain","year":"2004","journal-title":"Neuron"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Kopal, J., Vo, A., Tao, Q., Simuni, T., Chahine, L.M., Bzdok, D., and Dagher, A. (2026). Carriers of LRRK2 Pathogenic Variants Show a Milder, Anatomically Distinct Brain Signature of Parkinson\u2019s Disease. Commun. Med.","DOI":"10.1038\/s43856-025-01330-7"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng0395-267","article-title":"A Mutation in the Ceruloplasmin Gene Is Associated with Systemic Hemosiderosis in Humans","volume":"9","author":"Yoshida","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1096\/fj.04-3486fje","article-title":"Functional Relevance of Ceruloplasmin Mutations in Parkinson\u2019s Disease","volume":"19","author":"Hochstrasser","year":"2005","journal-title":"FASEB J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"105625","DOI":"10.1016\/j.ebiom.2025.105625","article-title":"Functional Characterisation of Missense Ceruloplasmin Variants and Real-World Prevalence Assessment of Aceruloplasminemia Using Population Data","volume":"113","author":"Ziliotto","year":"2025","journal-title":"eBioMedicine"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Tu, R., Han, Z., Zhang, H., Jia, X., Sun, T., Liu, H., Li, J., Tang, M., and Wang, S. (2025). From Pathogenesis to Treatment: The Emerging Role of Ferroptosis in Parkinson\u2019s Disease. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1709561"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Zaki, M.G., Jakova, E., Pordeli, M., Setork, E., Taghibiglou, C., and Cayabyab, F.S. (2025). The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson\u2019s Disease. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202505.0117.v1"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.bbih.2022.100544","article-title":"Extracellular Adenosine Induces Hypersecretion of IL-17A by T-Helper 17 Cells through the Adenosine A2a Receptor","volume":"26","author":"Tokano","year":"2022","journal-title":"Brain Behav. Immun.-Health"},{"key":"ref_110","first-page":"9952743","article-title":"Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors","volume":"2021","author":"Binde","year":"2021","journal-title":"Park. Dis."},{"key":"ref_111","first-page":"477","article-title":"Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson\u2019s Disease: Past, Present, and Future","volume":"12","author":"Tan","year":"2021","journal-title":"J. Park. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/mds.26724","article-title":"Long-Term Effects of Rasagiline and the Natural History of Treated Parkinson\u2019s Disease","volume":"31","author":"Rascol","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/jpet.102.042267","article-title":"Levodopa Is Toxic to Dopamine Neurons in an in Vitro but not an in Vivo Model of Oxidative Stress","volume":"304","author":"Mytilineou","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0891-5849(99)00075-1","article-title":"Peripheral Markers of Oxidative Stress in Parkinson\u2019s Disease. The Role of L-DOPA","volume":"27","author":"Martignoni","year":"1999","journal-title":"Free Radic. Biol. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"108101","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.108101","article-title":"Dopamine Receptor Agonist Pramipexole Exerts Neuroprotection on Global Cerebral Ischemia\/Reperfusion Injury by Inhibiting Ferroptosis","volume":"34","author":"Kang","year":"2025","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1474-4422(13)70117-0","article-title":"Pramipexole in Patients with Early Parkinson\u2019s Disease (PROUD): A Randomised Delayed-Start Trial","volume":"12","author":"Schapira","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group CALM Cohort Investigators (2009). Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease. JAMA Neurol., 66, 563\u2013570.","DOI":"10.1001\/archneur.66.1.nct90001"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole for the Treatment of Early Parkinson\u2019s Disease","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(05)70098-3","article-title":"Entacapone in the Treatment of Parkinson\u2019s Disease","volume":"4","author":"Schrag","year":"2005","journal-title":"Lancet Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1021\/acsptsci.4c00124","article-title":"Cellular and Mitochondrial Toxicity of Tolcapone, Entacapone, and New Nitrocatechol Derivatives","volume":"7","author":"Pinto","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_121","unstructured":"Brydon, L., and Kirsop, A. (2022). An Update of Opicapone in Parkinson\u2019s Disease: Evidence-Based Results of Recent Trials. CNS, 8."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Riederer, P., and M\u00fcller, T. (2022). Selegiline for Treating Parkinson\u2019s Disease. NeuroPsychopharmacotherapy, Springer.","DOI":"10.1007\/978-3-030-62059-2_237"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.51.2.520","article-title":"Selegiline Delays the Onset of Disability in de Novo Parkinsonian Patients. Swedish Parkinson Study Group","volume":"51","author":"Heinonen","year":"1998","journal-title":"Neurology"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (1989). DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson\u2019s Disease: Parkinson Study Group. JAMA Neurol., 46, 1052\u20131060.","DOI":"10.1001\/archneur.1989.00520460028009"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00702-020-02150-w","article-title":"Rasagiline and Selegiline Modulate Mitochondrial Homeostasis, Intervene Apoptosis System and Mitigate \u03b1-Synuclein Cytotoxicity in Disease-Modifying Therapy for Parkinson\u2019s Disease","volume":"127","author":"Naoi","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_126","first-page":"1","article-title":"FDA Committee: Rasagiline Rejected as \u2018Disease Modifying\u2019 for Parkinson Disease","volume":"11","author":"Hurley","year":"2011","journal-title":"Neurol. Today"},{"key":"ref_127","first-page":"105","article-title":"Neuroprotective Effects of Safinamide against Autophagy in 6-Hydroxydopamine-Induced SH-SY5Y Cell Model of Parkinson\u2019s Disease","volume":"14","author":"Yeo","year":"2024","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.drudis.2018.01.033","article-title":"Safinamide: A New Hope for Parkinson\u2019s Disease?","volume":"23","author":"Teixeira","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/neurolint12030017","article-title":"Istradefylline to Treat Patients with Parkinson\u2019s Disease Experiencing \u201cOff\u201d Episodes: A Comprehensive Review","volume":"12","author":"Berger","year":"2020","journal-title":"Neurol. Int."},{"key":"ref_130","first-page":"443","article-title":"Drug Repurposing of Dimethyl Fumarate in Parkinson\u2019s Disease: A Promising Disease-Modifying Strategy","volume":"29","author":"Gardoni","year":"2025","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.1523\/JNEUROSCI.0625-19.2019","article-title":"Akt Phosphorylates NQO1 and Triggers Its Degradation, Abolishing Its Antioxidative Activities in Parkinson\u2019s Disease","volume":"39","author":"Luo","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"637","DOI":"10.14336\/AD.2018.0513","article-title":"The Anti-Inflammatory and Anti-Oxidant Mechanisms of the Keap1\/Nrf2\/ARE Signaling Pathway in Chronic Diseases","volume":"10","author":"Tu","year":"2019","journal-title":"Aging Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17582024.2025.2563489","article-title":"N-Acetylcysteine for Parkinson\u2019s Disease: A Translational Systematic Review of Mechanistic and Early Clinical Data","volume":"15","author":"Mohammad","year":"2025","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"102494","DOI":"10.1016\/j.npep.2024.102494","article-title":"Antioxidant PRDX3 Gene Therapy Protects Brain Cells and Prevents Neurodegeneration in an Animal Model of Parkinson\u2019s Disease","volume":"110","year":"2025","journal-title":"Neuropeptides"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.bbabio.2008.03.029","article-title":"Targeting Lipophilic Cations to Mitochondria","volume":"1777","author":"Murphy","year":"2008","journal-title":"Biochim. Biophys. Acta BBA-Bioenerg."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"S40.004","DOI":"10.1212\/WNL.86.16_supplement.S40.004","article-title":"EPI-743 Improves Motor Function and CNS Biomarkers in PD: Results from a Phase 2A Pilot Trial (S40.004)","volume":"86","author":"Zesiewicz","year":"2016","journal-title":"Neurology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e08503","DOI":"10.1002\/advs.202408503","article-title":"NAD+-Boosters Improve Mitochondria Quality Control in Parkinson\u2019s Disease Models Via Mitochondrial UPR","volume":"12","author":"Zhou","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3892\/mmr.2014.2724","article-title":"Sirtuin 1 Activation Enhances the PGC-1\u03b1\/Mitochondrial Antioxidant System Pathway in Status Epilepticus","volume":"11","author":"Wang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1186\/s13063-022-06703-0","article-title":"Study in Parkinson\u2019s Disease of Exercise Phase 3 (SPARX3): Study Protocol for a Randomized Controlled Trial","volume":"23","author":"Patterson","year":"2022","journal-title":"Trials"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13813455.2025.2541698","article-title":"Mechanistic Insights into Ubiquinone Q10 in Parkinson\u2019s Disease: Mitochondrial Protection, Ferroptosis Inhibition, and Antioxidant Recycling","volume":"131","author":"Saadh","year":"2025","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"110942","DOI":"10.1016\/j.fct.2019.110942","article-title":"Upregulation of OPA1 by Carnosic Acid Is Mediated through Induction of IKK\u03b3 Ubiquitination by Parkin and Protects against Neurotoxicity","volume":"136","author":"Lin","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"124086","DOI":"10.1016\/j.lfs.2025.124086","article-title":"Drp1 in Parkinson\u2019s Disease: Mechanisms of Disease Pathology and the Promise of Targeted Therapeutic Strategies","volume":"384","author":"Liu","year":"2026","journal-title":"Life Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"eady0240","DOI":"10.1126\/sciadv.ady0240","article-title":"Putative PINK1\/Parkin Activators Lower the Threshold for Mitophagy by Sensitizing Cells to Mitochondrial Stress","volume":"11","author":"Rosencrans","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1242\/jcs.093849","article-title":"PINK1- and Parkin-Mediated Mitophagy at a Glance","volume":"125","author":"Jin","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tcb.2014.05.003","article-title":"Proteostasis Impairment in Protein-Misfolding and -Aggregation Diseases","volume":"24","author":"Hipp","year":"2014","journal-title":"Trends Cell Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol Effects in Glucocerebrosidase and A-synuclein Transgenic Mice","volume":"80","author":"Daly","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Hu, Y., Yang, Z., Wang, X., Li, X., and Wei, M. (2026). Oxidative Stress and Lysosomal Dysfunction in Neurodegenerative Diseases: Underlying Mechanisms and Nanotherapeutic Targeting Strategies. Antioxidants, 15.","DOI":"10.3390\/antiox15010073"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"105806","DOI":"10.1016\/j.nbd.2022.105806","article-title":"The Role of LRRK2 in the Periphery: Link with Parkinson\u2019s Disease and Inflammatory Diseases","volume":"172","author":"Tsafaras","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1186\/s12967-025-06354-0","article-title":"Recent Advances in Targeting LRRK2 for Parkinson\u2019s Disease Treatment","volume":"23","author":"Karami","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"E9115","DOI":"10.1073\/pnas.1812196115","article-title":"LRRK2 and Its Substrate Rab GTPases Are Sequentially Targeted onto Stressed Lysosomes and Maintain Their Homeostasis","volume":"115","author":"Eguchi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"107607","DOI":"10.1016\/j.parkreldis.2025.107607","article-title":"Rationale for LRRK2 Inhibition in Sporadic Parkinson\u2019s Disease and the LUMA Trial","volume":"134","author":"Hauser","year":"2025","journal-title":"Park. Relat. Disord."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Lang, A.E., Hauser, R.A., Kalia, L.V., Hersh, B., Berger, Z., Arenas, R.L., Paisan-Ruiz, C., Fraser, K., Jennings, D., and Kluss, J.H. (2025). LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson\u2019s Disease. Mov. Disord.","DOI":"10.1002\/mds.70100"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/mds.30307","article-title":"Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson\u2019s Disease","volume":"40","author":"Clarke","year":"2025","journal-title":"Mov. Disord."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Que, R., Zheng, J., Chang, Z., Zhang, W., Li, H., Xie, Z., Huang, Z., Wang, H.-T., Xu, J., and Jin, D. (2021). Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson\u2019s Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.794770"},{"key":"ref_155","first-page":"3800","article-title":"DL-3-n-Butylphthalide Therapy for Parkinson\u2019s Disease: A Randomized Controlled Trial","volume":"17","author":"Zhou","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e088069","DOI":"10.1002\/alz.088069","article-title":"The Neuroprotective Properties of GLP-1R Agonists Correlate with Their Ability to Cross the Blood-brain Barrier","volume":"20","author":"Holscher","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Diz-Chaves, Y., Mastoor, Z., Spuch, C., Gonz\u00e1lez-Mat\u00edas, L.C., and Mallo, F. (2022). Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179583"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide Once Weekly versus Placebo in Parkinson\u2019s Disease: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide Once a Week versus Placebo as a Potential Disease-Modifying Treatment for People with Parkinson\u2019s Disease in the UK: A Phase 3, Multicentre, Double-Blind, Parallel-Group, Randomised, Placebo-Controlled Trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"572","DOI":"10.18632\/aging.203835","article-title":"Combination of Dasatinib and Quercetin Improves Cognitive Abilities in Aged Male Wistar Rats, Alleviates Inflammation and Changes Hippocampal Synaptic Plasticity and Histone H3 Methylation Profile","volume":"14","author":"Krzystyniak","year":"2022","journal-title":"Aging"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Bresciani, G., Manai, F., Davinelli, S., Tucci, P., Saso, L., and Amadio, M. (2023). Novel Potential Pharmacological Applications of Dimethyl Fumarate\u2014An Overview and Update. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1264842"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41419-021-03507-z","article-title":"Targeted De-Repression of Neuronal Nrf2 Inhibits \u03b1-Synuclein Accumulation","volume":"12","author":"Baxter","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/med.21714","article-title":"Activation of Transcription Factor Nrf2 to Counteract Mitochondrial Dysfunction in Parkinson\u2019s Disease","volume":"41","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_164","first-page":"2075","article-title":"Bardoxolone Methyl (CDDO-Me) as a Therapeutic Agent: An Update on Its Pharmacokinetic and Pharmacodynamic Properties","volume":"8","author":"Wang","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmech.2017.04.008","article-title":"Design, Synthesis, and Evaluation of Curcumin Derivatives as Nrf2 Activators and Cytoprotectors against Oxidative Death","volume":"134","author":"Tu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"103781","DOI":"10.1016\/j.redox.2025.103781","article-title":"Advances in KEAP1-Based PROTACs as Emerging Therapeutic Modalities: Structural Basis and Progress","volume":"85","author":"Chen","year":"2025","journal-title":"Redox Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/dmd.117.078741","article-title":"Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells","volume":"46","author":"Li","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1016\/j.cellsig.2013.08.007","article-title":"Redox Activation of Nrf2 & NF-\u03baB: A Double End Sword?","volume":"25","author":"Zazueta","year":"2013","journal-title":"Cell. Signal."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/med.21567","article-title":"Dimethyl Fumarate, a Two-Edged Drug: Current Status and Future Directions","volume":"39","author":"Saidu","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/advances\/nmac001","article-title":"Dietary Antioxidants and Risk of Parkinson\u2019s Disease: A Systematic Review and Dose\u2013Response Meta-Analysis of Observational Studies","volume":"13","author":"Talebi","year":"2022","journal-title":"Adv. Nutr."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group QE3 Investigators, Beal, M.F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W.R., Haas, R., Juncos, J.L., Nutt, J.G., and Voss, T.S. (2014). A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurol., 71, 543\u2013552.","DOI":"10.1001\/jamaneurol.2014.131"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/1871527315666161104161855","article-title":"Meta-Analysis of Creatine for Neuroprotection Against Parkinson\u2019s Disease","volume":"16","author":"Attia","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Iftikhar, S., Sameer, H.M. (2023). Significant Potential of Melatonin Therapy in Parkinson\u2019s Disease\u2014A Meta-Analysis of Randomized Controlled Trials. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1265789"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Monti, D.A., Zabrecky, G., Kremens, D., Liang, T.-W., Wintering, N.A., Cai, J., Wei, X., Bazzan, A.J., Zhong, L., and Bowen, B. (2016). N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson\u2019s Disease: Preliminary Clinical and Cell Line Data. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157602"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s12640-022-00501-x","article-title":"Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: An Updated Review","volume":"40","author":"Banerjee","year":"2022","journal-title":"Neurotox. Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/mds.23148","article-title":"A Double-Blind Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant MitoQas a Disease-Modifying Therapy in Parkinson\u2019s Disease","volume":"25","author":"Snow","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1134\/S0006297917120100","article-title":"Effects of Mitochondrial Antioxidant SkQ1 on Biochemical and Behavioral Parameters in a Parkinsonism Model in Mice","volume":"82","author":"Pavshintsev","year":"2017","journal-title":"Biochem. Biokhimiia"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Tung, C., Varzideh, F., Farroni, E., Mone, P., Kansakar, U., Jankauskas, S.S., and Santulli, G. (2025). Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26030944"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2326409817733013","DOI":"10.1177\/2326409817733013","article-title":"Clinical Trials in Mitochondrial Disease: An Update on EPI-743 and RP103","volume":"5","author":"Enns","year":"2017","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s10020-025-01208-3","article-title":"The Interplay of Iron, Oxidative Stress, and \u03b1-Synuclein in Parkinson\u2019s Disease Progression","volume":"31","author":"Chen","year":"2025","journal-title":"Mol. Med."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Lin, K.-J., Chen, S.-D., Lin, K.-L., Liou, C.-W., Lan, M.-Y., Chuang, Y.-C., Wang, P.-W., Lee, J.-J., Wang, F.-S., and Lin, H.-Y. (2022). Iron Brain Menace: The Involvement of Ferroptosis in Parkinson Disease. Cells, 11.","DOI":"10.3390\/cells11233829"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1093\/brain\/awaf398","article-title":"Iron on Trial: Recasting the Role of Iron in Neurodegeneration","volume":"148","author":"Ayton","year":"2025","journal-title":"Brain"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.tips.2023.08.012","article-title":"Beyond Ferrostatin-1: A Comprehensive Review of Ferroptosis Inhibitors","volume":"44","author":"Scarpellini","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"110991","DOI":"10.1016\/j.brainresbull.2024.110991","article-title":"The Molecular Mechanism of Ferroptosis and Its Relationship with Parkinson\u2019s Disease","volume":"213","author":"Su","year":"2024","journal-title":"Brain Res. Bull."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41419-023-05716-0","article-title":"The Interaction between Ferroptosis and Inflammatory Signaling Pathways","volume":"14","author":"Chen","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","article-title":"Mitochondrial Dysfunction in Parkinson\u2019s Disease","volume":"24","author":"Moon","year":"2015","journal-title":"Exp. Neurobiol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e70657","DOI":"10.1111\/cns.70657","article-title":"AMPK\/SIRT1\/PGC-1\u03b1 Signaling Pathway: Molecular Mechanisms and Targeted Strategies from Energy Homeostasis Regulation to Disease Therapy","volume":"31","author":"Chen","year":"2025","journal-title":"CNS Neurosci. Ther."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s12640-021-00392-4","article-title":"SIRT1 Protects Dopaminergic Neurons in Parkinson\u2019s Disease Models via PGC-1\u03b1-Mediated Mitochondrial Biogenesis","volume":"39","author":"Chen","year":"2021","journal-title":"Neurotox. Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cmet.2022.02.001","article-title":"The NADPARK Study: A Randomized Phase I Trial of Nicotinamide Riboside Supplementation in Parkinson\u2019s Disease","volume":"34","author":"Brakedal","year":"2022","journal-title":"Cell Metab."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.4252\/wjsc.v13.i12.1928","article-title":"Urolithin a Alleviates Oxidative Stress-Induced Senescence in Nucleus Pulposus-Derived Mesenchymal Stem Cells through SIRT1\/PGC-1\u03b1 Pathway","volume":"13","author":"Shi","year":"2021","journal-title":"World J. Stem Cells"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1038\/s41598-024-55923-8","article-title":"Emerging Roles of SIRT1 Activator, SRT2104, in Disease Treatment","volume":"14","author":"Chang","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Maga\u00f1a, J.C., Deus, C.M., Gin\u00e9-Garriga, M., Montan\u00e9, J., and Pereira, S.P. (2022). Exercise-Boosted Mitochondrial Remodeling in Parkinson\u2019s Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123228"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Carneiro-Pereira, B., Ferreira-Antunes, F., Campos, J., Salgado, A.J., and Sampaio-Marques, B. (2025). Caloric Restriction Mimetics as Priming Agents of Mesenchymal Stem Cells Secretome to Enhance Regenerative Responses to Parkinson\u2019s Disease. Molecules, 30.","DOI":"10.3390\/molecules30112260"},{"key":"ref_194","first-page":"1452696","article-title":"PGC-1\u03b1, Inflammation, and Oxidative Stress: An Integrative View in Metabolism","volume":"2020","author":"Ortega","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12967-023-04270-9","article-title":"Inhibition of DRP1-Dependent Mitochondrial Fission by Mdivi-1 Alleviates Atherosclerosis through the Modulation of M1 Polarization","volume":"21","author":"Su","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12035-025-05484-2","article-title":"Inhibition of DRP1-Mediated Mitochondrial Fission and NRF2\/HO-1\/GPX4-Mediated Ferroptosis by Mdivi-1 Protects Against Vascular Cognitive Impairment","volume":"63","author":"Liu","year":"2026","journal-title":"Mol. Neurobiol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"114811","DOI":"10.1016\/j.bbr.2023.114811","article-title":"Mitochondrial Homeostasis Regulation: A Promising Therapeutic Target for Parkinson\u2019s Disease","volume":"459","author":"Yao","year":"2024","journal-title":"Behav. Brain Res."},{"key":"ref_198","first-page":"41","article-title":"Rethinking \u2018Rare\u2019 PINK1 Parkinson\u2019s Disease: A Meta-Analysis of Geographical Prevalence, Phenotypic Diversity, and \u03b1-Synuclein Pathology","volume":"15","author":"Yin","year":"2025","journal-title":"J. Park. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Blagov, A.V., Goncharov, A.G., Babich, O.O., Larina, V.V., Orekhov, A.N., and Melnichenko, A.A. (2022). Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson\u2019s Disease. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112514"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12975-023-01228-3","article-title":"Inhibition of USP30 Promotes Mitophagy by Regulating Ubiquitination of MFN2 by Parkin to Attenuate Early Brain Injury After SAH","volume":"16","author":"Liu","year":"2025","journal-title":"Transl. Stroke Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"15485","DOI":"10.1038\/s41598-020-72345-4","article-title":"Oxidative Switch Drives Mitophagy Defects in Dopaminergic Parkin Mutant Patient Neurons","volume":"10","author":"Schwartzentruber","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1007\/s12035-023-03530-5","article-title":"Metformin and Trehalose-Modulated Autophagy Exerts a Neurotherapeutic Effect on Parkinson\u2019s Disease","volume":"60","author":"Garcia","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Lin, M., Zhai, F., Chen, J., and Jin, X. (2024). Exploring the Role of Ubiquitin-Proteasome System in the Pathogenesis of Parkinson\u2019s Disease. Pharmaceuticals, 17.","DOI":"10.3390\/ph17060782"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1021\/acs.jmedchem.9b00101","article-title":"Proteasome Activation as a New Therapeutic Approach to Target Proteotoxic Disorders","volume":"62","author":"Njomen","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Lin, S.-C., Chang, C.-C., Tsou, S.-H., Chiu, P.-Y., Cheng, J.-F., Hung, H.-C., Chen, W.-J., Ho, Y.-J., and Lin, C.-L. (2024). Protective Effects of Ambroxol on A\u03b2 and \u03b1-Synuclein-Induced Neurotoxicity Through Glucocerebrosidase Activation in HT-22 Hippocampal Neuronal Cells. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212114"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol Improves Lysosomal Biochemistry in Glucocerebrosidase Mutation-Linked Parkinson Disease Cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-pharmtox-022124-033653","article-title":"Prospects for Disease Slowing in Parkinson Disease","volume":"65","author":"Menozzi","year":"2025","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the Treatment of Patients with Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_209","first-page":"S183","article-title":"Gene Therapy for Parkinson\u2019s Disease Associated with GBA1 Mutations","volume":"11","author":"Abeliovich","year":"2021","journal-title":"J. Park. Dis."},{"key":"ref_210","unstructured":"(2025, December 01). Prevail Therapeutics. A Phase 1\/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients with Parkinson\u2019s Disease with at Least One GBA1 Mutation (PROPEL). ClinicalTrials.gov Identifier: NCT04127578, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04127578."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"120822","DOI":"10.1016\/j.jns.2023.120822","article-title":"Non-Steroidal Anti-Inflammatory Drug Use and Markers of Parkinson\u2019s Disease Progression: A Retrospective Cohort Study","volume":"454","author":"Kuhlman","year":"2023","journal-title":"J. Neurol. Sci."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"e28838","DOI":"10.1016\/j.heliyon.2024.e28838","article-title":"Role of NLRP3 in Parkinson\u2019s Disease: Specific Activation Especially in Dopaminergic Neurons","volume":"10","author":"Yu","year":"2024","journal-title":"Heliyon"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.clinph.2022.01.036","article-title":"P 5 MCC950 Treatment Reduces Neuroinflammation, Rescues Neuronal Cell Death and Ameliorates Motor Deficits in the AAV1\/2-A53T-\u03b1Syn Mouse Model of Parkinson\u2019s Disease","volume":"137","author":"Grotemeyer","year":"2022","journal-title":"Clin. Neurophysiol."},{"key":"ref_214","unstructured":"(2025, December 09). Soluble Epoxide Hydrolase Plays a Key Role in the Pathogenesis of Parkinson\u2019s Disease. Available online: https:\/\/www.researchgate.net\/publication\/325035323_Soluble_epoxide_hydrolase_plays_a_key_role_in_the_pathogenesis_of_Parkinson%27s_disease."},{"key":"ref_215","unstructured":"EicOsis Human Health Inc (2025, December 01). A Single-Center, Double-Blind, Placebo-Controlled, Phase 1A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sequential Dose Regimens of Oral EC5026 in Healthy Male and Female Subjects. ClinicalTrials.gov Identifier: NCT04228302, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04228302."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.29297","article-title":"LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson\u2019s Disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Mov. Disord."},{"key":"ref_217","unstructured":"Biogen (2025, December 01). A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects with Parkinson\u2019s Disease. ClinicalTrials.gov Identifier: NCT04056689, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04056689."},{"key":"ref_218","first-page":"216298","article-title":"Transcriptional Factor NF-\u03baB as a Target for Therapy in Parkinson\u2019s Disease","volume":"2011","author":"Flood","year":"2011","journal-title":"Park. Dis."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s13098-025-01888-1","article-title":"GLP-1 Receptor Agonists in Parkinson\u2019s Disease: An Updated Comprehensive Systematic Review with Meta-Analysis","volume":"17","author":"Helal","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tma.2025.08.005","article-title":"A Comprehensive Review of the Multisystem Benefits of Antidiabetic Drugs in Aging beyond Glycemic Control","volume":"9","author":"Zohora","year":"2025","journal-title":"Transl. Med. Aging"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Du, H., Meng, X., Yao, Y., and Xu, J. (2022). The Mechanism and Efficacy of GLP-1 Receptor Agonists in the Treatment of Alzheimer\u2019s Disease. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1033479"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/nan.12689","article-title":"Cell Senescence in Neuropathology: A Focus on Neurodegeneration and Tumours","volume":"47","author":"Carreno","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/molpharm.123.000803","article-title":"Pharmacological Targeting of Senescence with Senolytics as a New Therapeutic Strategy for Neurodegeneration","volume":"105","author":"Richardson","year":"2024","journal-title":"Mol. Pharmacol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"100147","DOI":"10.1016\/j.neurop.2024.100147","article-title":"Genetics of Parkinson\u2019s Disease: Recessive Forms","volume":"4","author":"Salles","year":"2024","journal-title":"Neurol. Perspect."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1474-4422(25)00125-5","article-title":"Gene Therapy for Parkinson\u2019s Disease: Trials and Technical Advances","volume":"24","author":"Winston","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/mds.27193","article-title":"Neuropathology of Genetic Synucleinopathies with Parkinsonism\u2014Review of the Literature","volume":"32","author":"Schneider","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/bs.ant.2024.02.001","article-title":"Iron Toxicity, Ferroptosis and Microbiota in Parkinson\u2019s Disease: Implications for Novel Targets","volume":"11","author":"Carvalho","year":"2024","journal-title":"Adv. Neurotoxicol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"176936","DOI":"10.1016\/j.ejphar.2024.176936","article-title":"Beyond Insulin: The Intriguing Role of GLP-1 in Parkinson\u2019s Disease","volume":"982","author":"Verma","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41531-019-0091-7","article-title":"Deep Brain Stimulation and Genetic Variability in Parkinson\u2019s Disease: A Review of the Literature","volume":"5","author":"Ligaard","year":"2019","journal-title":"npj Park. Dis."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ana.26302","article-title":"Parkinson Disease and STN-DBS: Cognitive Effects in GBA Mutation Carriers","volume":"91","author":"Pal","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Guo, H., Shen, X., Lyu, M., Zhou, G., Chen, C., Xing, B., and Xie, Y. (2025). Research Progress of Multimodal Biomarkers in the Early Diagnosis of Mild Cognitive Impairment in Parkinson\u2019s Disease. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1652378"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"e200002","DOI":"10.1212\/NXG.0000000000200002","article-title":"Genome Sequencing in the Parkinson Disease Clinic","volume":"8","author":"Hill","year":"2022","journal-title":"Neurol. Genet."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acn3.644","article-title":"The Parkinson\u2019s Progression Markers Initiative (PPMI)\u2014Establishing a PD Biomarker Cohort","volume":"5","author":"Marek","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41531-022-00412-w","article-title":"Genetically-Informed Prediction of Short-Term Parkinson\u2019s Disease Progression","volume":"8","author":"Sadaei","year":"2022","journal-title":"npj Park. Dis."}],"container-title":["Antioxidants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3921\/15\/2\/187\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:04:15Z","timestamp":1770026655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3921\/15\/2\/187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":234,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["antiox15020187"],"URL":"https:\/\/doi.org\/10.3390\/antiox15020187","relation":{},"ISSN":["2076-3921"],"issn-type":[{"value":"2076-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}